Hims & Hers Retreats from Wegovy Copycat, Signaling a Shift in Telehealth Pharma
Hims & Hers has halted its sale of a compounded version of Novo Nordisk’s Wegovy, a move that represents a significant victory for the Danish pharmaceutical giant and underscores the increasing regulatory scrutiny facing telehealth companies offering compounded drugs. The decision comes swiftly after the FDA announced an investigation into companies marketing such alternatives.
The Rise and Fall of the $49 Wegovy
Just days ago, Hims & Hers announced a significantly cheaper alternative to Wegovy, priced at $49 a month, utilizing semaglutide, the active ingredient in Novo Nordisk’s branded medication. Novo Nordisk, which launched the oral version of Wegovy in the U.S. In early January at $149 a month, swiftly condemned the move as “illegal mass compounding” and threatened legal action. The initial announcement of the cheaper alternative briefly boosted Hims’ stock, but it quickly reversed course following Novo’s strong response and the FDA’s investigation.
Legal Battles and Patent Protection
Analysts highlighted the substantial legal risks Hims & Hers faced, given that Wegovy is protected by a patent. This legal vulnerability, combined with the FDA’s scrutiny, appears to have forced Hims & Hers to abandon its discounted offering. Hims’ share price experienced a significant decline, falling approximately 15% after the FDA’s announcement, reaching its lowest point since November 2024.
FDA Scrutiny and the Compounding Pharmacy Landscape
The FDA’s investigation extends beyond Hims & Hers, encompassing other companies offering compounded weight-loss drugs. This increased oversight stems, in part, from concerns raised about advertising claims made by these companies, including those featured in Hims & Hers’ 2025 Super Bowl commercial. The FDA previously issued warning letters to drug companies regarding misleading advertising practices.
Beyond Weight Loss: Hims & Hers Diversification Strategy
This setback for Hims & Hers comes as the company attempts to broaden its product portfolio beyond cheaper versions of popular drugs from Novo Nordisk and Eli Lilly. The company is actively seeking to diversify its offerings, but faces challenges in navigating the complex regulatory landscape and potential legal battles.
The Super Bowl Spotlight and Future Advertising
Despite the recent challenges, Hims & Hers is scheduled to air a Super Bowl advertisement on Sunday. This high-profile marketing effort will be closely watched, particularly in light of the FDA’s recent actions and concerns about advertising claims.
The Impact on Novo Nordisk and Eli Lilly
The news of Hims & Hers’ retreat led to a drop in the shares of both Novo Nordisk and Eli Lilly, though the impact was less severe than the initial reaction to Hims’ announcement. This suggests that the market had already factored in the potential for legal challenges and regulatory intervention.
FAQ
Q: What is compounding?
A: Compounding is the practice of combining, mixing, or altering ingredients to create a medication tailored to an individual patient’s needs.
Q: What is semaglutide?
A: Semaglutide is the active ingredient in both Wegovy and Ozempic, used for weight loss and managing type 2 diabetes.
Q: What does this indicate for patients seeking affordable weight loss options?
A: Patients may require to explore other options, such as manufacturer coupons or patient assistance programs, or discuss alternative treatments with their healthcare provider.
Q: Will the FDA continue to investigate other companies offering compounded drugs?
A: Yes, the FDA has indicated that its investigation is ongoing and will encompass other companies offering compounded weight-loss drugs.
Did you know? Novo Nordisk ended its partnership with Hims & Hers in July 2025, prior to the recent events surrounding the Wegovy copycat.
Pro Tip: Always consult with a qualified healthcare professional before starting any new medication or treatment, including compounded drugs.
Stay informed about the latest developments in telehealth and pharmaceutical regulations. Explore our other articles on healthcare innovation and pharmaceutical law.
What are your thoughts on the future of compounded medications? Share your opinions in the comments below!